Changes of the prescription of hormone therapy in menopausal women: An observational study in Taiwan

Weng-Foung Huang; Yi-Wen Tsai; Fei-Yuan Hsiao; Wen-Chun Liu
January 2007
BMC Public Health;2007, Vol. 7 Issue 1, p56
Academic Journal
Background: To evaluate the impact of the 2002 Women's Health Initiative (WHI) study results on the prescription of menopausal hormone therapy (MHT) to treat menopause-related symptoms in Taiwan. Methods: This retrospective study participant data collected from women interviewed in 2001 Taiwan's National Health Interview Survey (NHIS) and the National Health Insurance (NHI) outpatient claims for women being treated for menopause-related symptoms. We compared prescriptions made for MHI to women seeking outpatient treatment for menopause-related symptoms before and after the publication of the 2002 WHI to study its effect of prescription behavior in Taiwan. There was one dichotomous outcome variable, which was whether MHT was prescribed or not in an outpatient visit to treat menopause-related symptoms. Results: Our study included 504 women 45 years old or above whose outpatient visits for menopause-related symptoms were covered by National Health Insurance in 2002. In total, these 504 women made 2549 outpatient visits to be treated for these symptoms. The proportion of outpatient visits in which MHT was prescribed dropped from 83.0% (n = 1,155) before WHI to 73.0% (n = 844) after WHI. We found a decrease in likelihood that women would be prescribed MHT for menopause-related symptoms after the release of the WHI report (OR = 0.36, 95%CI = 0.25 to 0.52, p < 0.05). Gynecologists and obstetricians are more likely to prescribe MHT than physicians with other medical specialties (5.34; 95%CI = 3.45 to 8.26, p < 0.05). Women with college level educations or higher became less likely to be prescribed MHT (Model 2; OR 0.30; 95% CI 0.11-0.83), and academic medical centers became less likely to prescribe MHT than other medical care institutions (Model 3; OR 0.15; 95% CI 0.34-0.63). Conclusion: The WHI report caused a substantial decline in the use of MHT to treat menopause-related symptoms in Taiwan. It was found to exert most of its influence in patients with higher educations, physicians with specialties other than gynecologists and obstetricians, and academic medical centers.


Related Articles

  • High-Dose Soy Isoflavones Relieve Menopausal Symptoms. Walling, Anne D. // American Family Physician;5/15/2002, Vol. 65 Issue 10, p2143 

    Presents information on a study by K.K. Han and others that evaluated treatment of menopausal symptoms with 100 mg of soy isoflavone per day. Description of the study and its results; Conclusion that 100 mg per day of isoflavone effectively relieved menopausal symptoms, especially vasomotor...

  • Adverse Reaction Research.  // Reactions Weekly;10/6/2007, Issue 1172, p4 

    The article reports on a study which revealed the awareness of some women concerning the results of a landmark hormone therapy study conducted in the U.S. The study identified risks associated with hormone therapy among postmenopausal women. A nationally representative survey has been conducted...

  • Management of Postmenopausal Vaginal Symptoms in Women. Bond, Sharon; Horton, Lenora S. // Journal of Gerontological Nursing;Jul2010, Vol. 36 Issue 7, p3 

    Although menopause is a normal, physiological process in the lives of women, many report uncomfortable urogenital symptoms as they transition through this stage. Such symptoms include urinary frequency, increased urinary tract infections, vaginal dryness and irritation, and painful intercourse,...

  • HRT underused by menopausal women despite need for treatment.  // PharmacoEconomics & Outcomes News;3/26/2005, Issue 474, p11 

    Presents the results of a survey on the attitude of women toward the use of hormone replacement therapy in the treatment of menopausal symptoms. Percentage of women who believe that menopausal symptoms require treatment; Potential reasons behind a negative opinion of the women toward the...

  • Counseling Patients About Hormone Therapy and Alternatives for Menopausal Symptoms. HILL, D. ASHLEY; HILL, SUSAN R. // American Family Physician;10/1/2010, Vol. 82 Issue 7, p801 

    The results of recent large clinical trials have led physicians and patients to question the safety of menopausal hormone therapy. In the past, physicians prescribed hormone therapy in an attempt to improve overall health and prevent cardiac disease. Hormone therapy appears to increase the risk...

  • New findings support a soy-rich diet.  // Food Manufacture;Feb2001, Vol. 76 Issue 2, p18 

    Presents research on postmenopausal women consuming soya-rich diet for stronger bones in Great Britain. Importance of oestrogen in soya to alleviate symptoms of menopause; Signs and symptoms of menopause; Disadvantages of isoflavones found in soya.

  • Czy akupunktura jest skuteczna w leczeniu uderzeÅ„ gorÄ…ca? Woźniak, Piotr; Ziółkowski, Paweł; Stetkiewicz, Tomasz; Pięta-Dolińska, Agnieszka; Oszukowski, Przemysław // Menopausal Review / Przeglad Menopauzalny;2012, Vol. 11 Issue 4, p319 

    The menopause is a successive stage of the woman's life, during which the quality of her life decreases very frequently due to the occurrence of many diseases and symptoms, among others, the perimenopausal symptoms such as hot flashes. Hot flashes and hidrosis as their night equivalent, appear...

  • Alternatives to HRT used by half in menopause.  // GP: General Practitioner;6/8/2007, p1 

    The article presents information related to a survey which has revealed that nearly half of all postmenopausal women in Great Britain seek alternative therapies to hormone replacement therapy (HRT), despite admitting to not knowing enough about them. The survey was conducted by the Royal Society...

  • European active surveillance study of women taking HRT (EURAS-HRT): study protocol [NCT00214903]. Dinger, Juergen C.; Heinemann, Lothar A. J. // BMC Women's Health;2006, Vol. 6, p1 

    Background: The post marketing safety surveillance program for a drug containing a new chemical entity should assess both, the safety outcomes that relate specifically to the targeted population, as well as those that could potentially be related to special pharmacological characteristics of the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics